AUS
NZ
UK
CA
USA
IND
Highlights
Novo Resources identifies high-grade gold intercepts at Tibooburra Gold Project in NSW
Orthocell reports record FY2025 revenue, advancing regenerative medicine footprint
Resolution Minerals gears up for major drilling at Horse Heaven Project in the US
Companies within the ASX Small Ordinaries index delivered an active mix of updates, with several names reporting key progress across mining exploration, biotech trials, and material processing. Despite broader weakness in the market, multiple small caps released significant operational developments.
The index tracks small-cap players across diverse sectors including resources, healthcare, and technology, offering a look into emerging growth trends that stand apart from larger market benchmarks.
Novo Resources uncovers high-grade gold at NSW drilling site
Novo Resources Ltd (asx:nvo) has released promising assay results from its Clone prospect within the Tibooburra Gold Project located in northwestern New South Wales. The company's reverse circulation program, which included multiple drill holes over a defined strike area, returned several strong intercepts that suggest consistent grade and mineral continuity near surface.
The latest drilling activity has identified a gold shoot that extends across a significant strike length. Novo says these results reinforce its ongoing exploration strategy in the region.
Orthocell delivers record revenue for FY2025
Orthocell Ltd (asx:occ) reported its highest-ever full-year revenue, supported by increased sales from its regenerative medicine platform. Growth was driven by traction for Remplir™, the company's nerve repair solution, which recently received regulatory clearance in the United States.
The company highlighted strong quarterly performance and expanding adoption across core and emerging markets. It marks the fifth consecutive quarter of growth for the regenerative biotech group.
Resolution Minerals begins countdown to Idaho drilling
Resolution Minerals Ltd (asx:rml) is preparing to commence drilling at its Horse Heaven Project in Idaho, following federal approval of its Plan of Operations. The campaign is set to explore targets across existing access roads, focusing on both precious and strategic minerals including antimony, gold, and tungsten.
The Phase 1 program will initially test the Golden Gate zone, building on earlier data from oxide and sulphide layers. The project adds to the company's North American exploration portfolio as it builds momentum toward its field mobilisation timeline.
American Rare Earths reports metallurgical success at Wyoming site
American Rare Earths Ltd (asx:arr) has shared metallurgical test results from its Halleck Creek Project in Wyoming. The Cowboy State Mine trials delivered strong recoveries for both light and heavy rare earth elements, supporting the project's future development path.
The company also reported reductions in impurity concentrations, selecting atmospheric tank leaching as the preferred processing method for its operational and environmental efficiency.
Prescient Therapeutics advances Phase 2 for cancer candidate
Prescient Therapeutics Ltd (asx:ptx) confirmed the progression of its PTX-100 program into Phase 2 clinical trials, targeting T-Cell Lymphomas. The treatment candidate is the only known GGT-1 inhibitor under clinical development, building on earlier-stage results.
The biotech has positioned PTX-100 as a key pillar in its oncology pipeline, focused on advancing treatment solutions in aggressive hematological conditions.
Askari Metals to outline Ethiopian gold project strategy
Askari Metals Ltd (asx:as2) will host a public briefing to discuss its acquisition of the Nejo Gold Project in Ethiopia. The event will feature strategic commentary on the significance of the acquisition and how it fits within the company’s broader exploration goals.
